Evidence map›Paper›PMID 39900767›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Applying AI/ML for Analyzing Gene Expression Patterns.

Zeeshan Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Zeeshan AhmedDepartment of Medicine, Division of Cardiovascular Disease and Hypertension, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. zahmed@ifh.rutgers.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) and machine learning (ML) have advanced in several areas and fields of life; however, its progress in the field of genomics is not matching the levels others have achieved. Challenges include but are not limited to the handling and analysis of high volumes of complex genomic data, and the expertise needed to implement and execute AI/ML approaches. In this chapter, we highlight the importance of transcriptomics, and RNA-seq driven gene expression data exploration to discover novel biomarkers and predict rare, common, and complex diseases. We discuss relevant high volume sequence data generated in the recent past and its availability through various channels, development of orthodox bioinformatics tools and technologies to investigate significantly expressed and abundantly enriched genes, and the implementation of cutting-edge AI/ML approaches to observe disease specific patterns. Current challenges include but are not limited to the acceptance of AI/ML in the scientific research and clinical environments, especially in providing personalized diagnoses and treatments. Reasons include unavailability of user-friendly AI/ML applications and reproducible results. Addressing these issues, we discuss our recently developed Findable, Accessible, Intelligent, and Reproducible (FAIR) solutions, designed for the users with and without computational background to discover biomarkers and predict diseases with high accuracy. We strongly believe that the rightful application of AI/ML techniques has the potential to open avenues for broader research, ultimately leading to personalized interventions and novel treatment targets. Its widespread application will contribute to the public health at large in the United States and around the globe.

Indexed as

Artificial IntelligenceComputational BiologyGene Expression ProfilingMachine LearningTranscriptomeGenomicsHumansRNA-SeqArtificial intelligenceExpressionGenePatternsPrecision medicine

Identifiers

PMID39900767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.